Trial Profile
First-in-human, phase I dose-escalation study of the pharmacokinetics and safety of single and multiple doses of a first-in-class enhancer of fluoropyrimidines, dUTPase inhibitor (TAS-114) in healthy male volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 20 May 2016
Price :
$35
*
At a glance
- Drugs TAS 114 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man; Pharmacokinetics
- Sponsors Taiho Pharmaceutical
- 29 Oct 2013 New trial record
- 21 Oct 2013 Results presented at the 25th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.